Evogene Ltd.

As of June 30, 2026, Evogene Ltd carries a market capitalization of 1.73B, placing it among publicly traded companies globally. Its enterprise value stands at 2.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Evogene Ltd's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Evogene Ltd has 13.54M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.24, and the price-to-book ratio stands at -1.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.27B versus a market cap of 1.73B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Evogene Ltd maintains a current ratio of 3.57, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.43, indicating elevated leverage, while an interest coverage ratio of -4.09 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -38.31, reflecting losses generated across the asset base. The company generates approximately 5.68M in revenue per employee across its workforce of 68.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.71 indicates how many times Evogene Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Evogene Ltd recorded 1.48M in income tax expense. The company reported a pretax loss of -4.61B and -2.69B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Evogene Ltd's stock has declined approximately 73.12% over the past 52 weeks. The 50-day moving average sits at 151.74, while the 200-day moving average is 216.65.

Over the twelve months ended June 30, 2026, Evogene Ltd generated 387.39M in revenue and converted that into -2.69B in net income, yielding earnings per share of -468.78. EBITDA reached -3.78B, while operating income came in at -4.05B.

As of June 30, 2026, Evogene Ltd holds 2.76B in cash and equivalents against 622.73M in total debt, resulting in a net debt position of -2.76B. Total book value stands at -975.14M, with working capital of 2.31B providing operational flexibility.

Evogene Ltd produced -3.24B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.82M in capital expenditures, free cash flow totaled -3.25B - equivalent to -330.32 per share.

Over the twelve months ended June 30, 2026, Evogene Ltd posted a gross margin of -112.47, reflecting its pricing power and cost economics. The operating margin of -1,044.30 and net profit margin of -694.19 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Evogene Ltd paid dividends of 80.46 per share. The dividend payout ratio of -18.67 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -258.87: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 161.91, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Evogene Ltd shareholders.

Evogene Ltd's most recent stock split took place on July 28, 2024 with a 10:1 split ratio.

As of June 30, 2026, Evogene Ltd has an Altman Z-Score of -32.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.